Evidence map›Paper›PMID 40514553›Full record

ArticleCurrent microbiology2025

A New Vaccine Candidate Expressing JUNV GP1-GP2 Against Argentine Hemorrhagic Fever Based on Baculovirus Surface Display.

Carla Tomatis, Mara C A M Aguiar, Nancy Charo, Silvia Aquila, Pablo D Thomas, Paula N Arrías, Matías L Pidre, Víctor Romanowski, Laura Riera, Julia Brignone and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Carla TomatisLaboratorio de Patogénesis Viral, Instituto de Biotecnología y Biología Molecular (IBBM), CONICET-UNLP, Calle 49 y 115, 1900, La Plata, Buenos Aires, Argentina.
Mara C A M AguiarLaboratorio de Trombosis Experimental, Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina, Buenos Aires, Argentina.
Nancy CharoLaboratorio de Trombosis Experimental, Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina, Buenos Aires, Argentina.
Silvia AquilaLaboratorio de Patogénesis Viral, Instituto de Biotecnología y Biología Molecular (IBBM), CONICET-UNLP, Calle 49 y 115, 1900, La Plata, Buenos Aires, Argentina.
Pablo D ThomasLaboratorio de Patogénesis Viral, Instituto de Biotecnología y Biología Molecular (IBBM), CONICET-UNLP, Calle 49 y 115, 1900, La Plata, Buenos Aires, Argentina.
Paula N ArríasLaboratorio de Virología Molecular, Instituto de Biotecnología y Biología Molecular (IBBM), CONICET-UNLP, La Plata, Buenos Aires, Argentina.
Matías L PidreLaboratorio de Virología Molecular, Instituto de Biotecnología y Biología Molecular (IBBM), CONICET-UNLP, La Plata, Buenos Aires, Argentina.
Víctor RomanowskiLaboratorio de Virología Molecular, Instituto de Biotecnología y Biología Molecular (IBBM), CONICET-UNLP, La Plata, Buenos Aires, Argentina.
Laura RieraInstituto Nacional de Enfermedades Virales Humanas (INEVH), ANLIS Malbrán, Pergamino, Argentina.
Julia BrignoneInstituto Nacional de Enfermedades Virales Humanas (INEVH), ANLIS Malbrán, Pergamino, Argentina.
Andrea MaizaInstituto Nacional de Enfermedades Virales Humanas (INEVH), ANLIS Malbrán, Pergamino, Argentina.
Eugenio Antonio Carrera SilvaLaboratorio de Trombosis Experimental, Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina, Buenos Aires, Argentina.
María Florencia FerrerLaboratorio de Patogénesis Viral, Instituto de Biotecnología y Biología Molecular (IBBM), CONICET-UNLP, Calle 49 y 115, 1900, La Plata, Buenos Aires, Argentina. mflorenciaferrer@yahoo.com.
Ricardo Martín GómezLaboratorio de Patogénesis Viral, Instituto de Biotecnología y Biología Molecular (IBBM), CONICET-UNLP, Calle 49 y 115, 1900, La Plata, Buenos Aires, Argentina. rmg1426@gmail.com.

Funding

Fondo para la Investigación Científica y Tecnológica PCE 2018-0003Fondo para la Investigación Científica y Tecnológica PICT 2019- 0767Fondo para la Investigación Científica y Tecnológica PICT 2020-2702
6 · The paper itself

Abstract

With the aim of developing a new vaccine candidate using a recombinant baculovirus (rBV) expressing the Junín virus (JUNV) GP1 and GP2 proteins on its surface, a pBacPAK9 vector containing the BV-GP64 signal peptide, the JUNV GP1-GP2 and the transmembrane domain of the vesicular stomatitis virus G (VSV-G) protein were synthesized. This plasmid was co-transfected with the bApGOZA bacmid into Sf9 cells. The rBV was recovered from the supernatant. Protein expression was confirmed with a human serum by Western blot and with an anti-GPC monoclonal antibody by IFI staining and virometry. In an ELISA test, mice immunized with rBV exhibited specific antibody levels that also showed neutralizing properties in a plaque reduction test compared to controls. Guinea pigs immunized with rBV and challenged with JUNV showed partial protection compared to the Candid#1 vaccine. We have developed an rBV surface display platform to validate a potential JUNV vaccine candidate.

Indexed as

BaculoviridaeHemorrhagic Fever, AmericanJunin virusViral Envelope ProteinsViral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleGuinea PigsHumansMiceMice, Inbred BALB CSf9 CellsVaccines, SyntheticAntibodies, NeutralizingAntibodies, ViralVaccines, SyntheticViral Envelope ProteinsViral Vaccines

Identifiers

PMID40514553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.